pre-IPO PHARMA

COMPANY OVERVIEW

Gilgamesh is a pioneering mental health science-focused, biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE's) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.gilgameshpharmaceutical.com.


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 21, 2023

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020


Dec 15, 2022

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments


Mar 24, 2022

Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022


Nov 11, 2021

Gilgamesh Builds Team of Pharmaceutical Industry Leaders and Appoints New Members to Board of Directors


May 6, 2021

Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round


For More Press Releases


Google Analytics Alternative